Quidel Corp. recently announced that it expected fourth quarter revenue to be in the range of $53 million to $54 million.

Shares for the medical diagnostic test maker closed at a new 52-week high, at $21.64, on the day of the announcement — up 8 percent from the previous close. Quidel shares, which trade on the Nasdaq as QDEL, had ranged between $14.08 and $20.10 during the previous year.

“We saw a sudden and early onset to this year’s influenza season. I am pleased, however, with how well we were able to respond to the increased and rapid demand for our flu tests,” said Douglas Bryant, the company’s president and chief executive officer.

Quidel also announced that it had placed more than 3,000 of its Sofia medical instruments in the market, a greater number than it had forecast.

Quidel said that it will release its quarterly and annual revenue figures in February.

— SDBJ Staff Report